Metraipolis › archive › dc_144bb812dfb4

From Clinical Trial Efficacy to Real-World Effectiveness and Safety: Two-Year Outcomes of Cladribine in Relapsing-Remitting Multiple Sclerosis — Europe PMC PMID:42452581

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42452581
DOI
10.3390/jcm15135121
License (as archived)
solo-consultazione
Archived
2026-10-18T13:46:27.837Z
SHA-256 of the archived text
97d98cfdb2b2a82cd8be5458c7b85f4837767f08d60f10bdd30a9d5c1b9ff727
Stable URL of this page
https://metraipolis.com/documento/dc_144bb812dfb4

How to cite

From Clinical Trial Efficacy to Real-World Effectiveness and Safety: Two-Year Outcomes of Cladribine in Relapsing-Remitting Multiple Sclerosis — Europe PMC PMID:42452581 — Europe PMC (en), https://europepmc.org/article/MED/42452581 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_144bb812dfb4 (Metraipolis archive dc_144bb812dfb4, sha256 97d98cfdb2b2a82cd8be5458c7b85f4837767f08d60f10bdd30a9d5c1b9ff727)
BibTeX
@misc{dc144bb812dfb4,
  title = {From Clinical Trial Efficacy to Real-World Effectiveness and Safety: Two-Year Outcomes of Cladribine in Relapsing-Remitting Multiple Sclerosis — Europe PMC PMID:42452581},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42452581},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_144bb812dfb4; sha256 97d98cfdb2b2a82cd8be5458c7b85f4837767f08d60f10bdd30a9d5c1b9ff727},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42452581. Agents can read the archived copy with the MCP tool read_document.